These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33059317)

  • 1. How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists.
    Yasutaka Y; Fujioka S; Mishima T; Shibaguchi H; Tsuboi Y; Kamimura H
    Clin Neurol Neurosurg; 2020 Dec; 199():106266. PubMed ID: 33059317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
    Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
    Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continued Use of Rotigotine Transdermal Patches for Parkinson Disease].
    Yasutaka Y; Fujioka S; Shibaguchi H; Imakyure O; Washiyama A; Tsuboi Y; Futagami K
    Brain Nerve; 2016 Jun; 68(6):655-60. PubMed ID: 27279164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
    Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
    Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on rotigotine in Parkinson's disease.
    Baldwin CM; Keating GM
    Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
    Raison-Peyron N; Guillot B
    Contact Dermatitis; 2016 Aug; 75(2):121-2. PubMed ID: 27385523
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of Topical Agents for Symptomatic Treatment of Rotigotine Patch-Induced Skin Disorders].
    Yasutaka Y; Fujioka S; Shibaguchi H; Kiyomi F; Hara K; Ogata K; Tsuboi Y; Kamimura H
    Brain Nerve; 2017 Sep; 69(9):1047-1053. PubMed ID: 28900068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
    Baldwin CM; Keating GM
    CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
    Raeder V; Boura I; Leta V; Jenner P; Reichmann H; Trenkwalder C; Klingelhoefer L; Chaudhuri KR
    CNS Drugs; 2021 Feb; 35(2):215-231. PubMed ID: 33559846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
    Frampton JE
    CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.